Zentalis Pharma Prices $80.5 Mln Offering Of Shares At $3.50 Per Share; Stock Down

Zentalis Pharmaceuticals priced a public offering of 23 million shares at $3.50 per share, raising expected gross proceeds of $80.5 million. The deal likely introduces near-term dilution risk (negative sentiment) for ZNTL, though the proceeds are intended to support ongoing corporate plans (net proceeds use not fully disclosed in the excerpt).

Analysis

Zentalis Pharmaceuticals priced a public offering of 23 million shares at $3.50 per share, raising expected gross proceeds of $80.5 million. The deal likely introduces near-term dilution risk (negative sentiment) for ZNTL, though the proceeds are intended to support ongoing corporate plans (net proceeds use not fully disclosed in the excerpt).